– ENTR-601-44 demonstrated significant plasma concentration, muscle concentration and exon skipping, at levels that suggest the potential for a clinically meaningful starting dose in planned upcoming patient trials – "We are excited to present the first clinical data from our Duchenne franchise, led by ENTR-601-44. ENTR601-44 was well tolerated in healthy volunteers and we are pleased to see significant plasma concentration, muscle concentration and exon skipping. We achieved the goals of the ENTR-601-44-10 ...

Shares of Entrada Therapeutics, Inc. (TRDA) have gained 17% over the past four weeks to close the last trading session at $15.32, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $21 indicates a potential upside of 37.1%. The average comprises three short-term price targets ranging from a low of $18 to a high of $25, with a standard deviation of $3.61. While the lowest estimate i ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q ____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40969 ___________________ ...

Clinical Trials - The company initiated dosing for the fourth and final cohort of its Phase 1 clinical trial of ENTR-601-44 for DMD, with data readout expected in October 2024[1]. - The company expects to submit regulatory applications in Q4 2024 for independent global Phase 2 clinical development studies for ENTR-601-44 and ENTR-601-45[3]. Financial Performance - Collaboration revenue for Q1 2024 was $59.1 million, a significant increase from $25.3 million in Q1 2023, primarily due to a clinical advancement milestone[6]. - The company reported a net income of $23.5 million for Q1 2024, compared to a net loss of $(6.7) million for the same period in 2023[8]. - Total operating expenses for Q1 2024 were $38.0 million, compared to $31.0 million for the same period in 2023[14]. Cash Position - Cash, cash equivalents, and marketable securities totaled $327.4 million as of March 31, 2024, down from $352.0 million as of December 31, 2023, with a cash runway expected through Q2 2026[5]. - A milestone payment of $75 million from Vertex is expected to be received in Q2 2024, contributing to the company's cash position[4]. - The company is eligible to receive up to $485 million in total from its collaboration with Vertex, including milestones and royalties on future net sales[4]. Expenses - Research and development expenses increased to $28.6 million in Q1 2024 from $23.1 million in Q1 2023, driven by the progression of clinical trials and higher personnel costs[7]. - General and administrative expenses rose to $9.4 million in Q1 2024 from $7.9 million in Q1 2023, mainly due to increased personnel costs[8].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40969 ENTRADA THERAPEUTICS, INC. FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 (Exact name of registrant as specified in its charter) Delaware 81-3983399 (State ...

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results – Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 – – Completed dosing for third cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for the second half of 2024 – – Regulatory applications expected in the fourth quarter of 2024 for the global Phase 2 clinical development ...

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q ____________________________ (Mark One) For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40969 _______________ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q ____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Indicate by check mark whether the registrant has subm ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ ENTRADA THERAPEUTICS, INC. FORM 10-Q ____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 00 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or (I.R.S. Employer Identification Number) 6 Tide Street Boston , MA 02210 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40969 ENTRADA THERAPEUTICS, INC. (Exact na ...